Why Array Technologies, Inc. (ARRY) is a Top Value Stock for the Long-Term

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, helping investors select stocks with high potential for market outperformance [3] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks based on value, growth, and momentum characteristics, assigning ratings from A to F [4] - Value Score focuses on identifying undervalued stocks using financial ratios [4] - Growth Score evaluates a company's financial health and future growth potential [5] - Momentum Score identifies optimal times to invest based on price trends and earnings estimates [6] - VGM Score combines all three styles, providing a comprehensive rating for stocks [7] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988 [8] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for optimal returns [10] Company Spotlight: Array Technologies, Inc. - Array Technologies, Inc. is a biopharmaceutical company focused on targeted small molecule drugs for cancer treatment [12] - The company has a marketed therapy, Braftovi plus Mektovi, approved for specific melanoma cases [12] - Array Technologies holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong investment potential [13] - The company has a forward P/E ratio of 10.83, appealing to value investors [13] - Recent upward revisions in earnings estimates suggest positive momentum, with a consensus estimate of $0.66 per share for fiscal 2025 [13] - With solid rankings and scores, Array Technologies is recommended for investors [14]